News Health
News Health. MILAN, Italy — Two impartial efforts to make use of synthetic intelligence (AI) to foretell the event of early rheumatoid.
Read Newshealth.biz news digest here: view the latest News Health articles and content updates right away or get to their most visited pages. Newshealth.biz is not yet rated by Alexa and its traffic estimate is unavailable. We haven’t detected security issues or inappropriate content on Newshealth.biz and thus you can safely use it. Newshealth.biz is hosted with CloudFlare, Inc. (United States) and its basic language is English.
- Content verdict: Safe
- Website availability: Live
- Language: English
- Last check:
-
N/A
Visitors daily -
N/A
Pageviews daily -
N/A
Google PR -
N/A
Alexa rank
Best pages on Newshealth.biz
-
The Leading Health News Journal
Newshealth.biz news digest
-
4 years
S. Korea Finds Some Liquid E-Cigarette Products Have Ingredient Linked to Lung I...
SEOUL (Reuters) – South Korean health authorities have found vitamin E acetate, which may be linked to lung illnesses, in some liquid e-cigarette products made by Juul Labs and KT&G, they said on Thursday, but the two companies denied using the material...
-
4 years
MLB Removes Marijuana From ‘Drugs of Abuse’, to Test Major League Players for Op...
NEW YORK (Reuters) – Major League Baseball (MLB) will remove marijuana from its list of banned substances and players who test positive for opioids, fentanyl, cocaine and synthetic THC under random drug tests will be referred for treatment before being...
-
4 years
Biosimilar for Crohn’s Noninferior to Adalimumab
In patients with moderate or severe active Crohn’s disease, the adalimumab biosimilar BI 695501 (Boehringer Ingelheim) is as safe and effective as adalimumab (Humira, AbbVie), new results from a phase 3 trial suggest.
This is the first randomized controlled study to compare the biosimilar with adalimumab specifically in Crohn’s patients, opening the door to less-costly treatment options for this group, said lead investigator Stephen Hanauer, MD, from Northwestern... -
4 years
Bristol-Myers wins $752 million in U.S. patent case against Gilead
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau
(Reuters) – Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer....
Domain history
Web host: | CloudFlare, Inc. |
Registrar: | |
Registrant: | REDACTED FOR PRIVACY (Private Person) |
Updated: | May 17, 2022 |
Expires: | July 10, 2023 |
Created: | July 10, 2017 |
Whois record
Safety scores
Trustworthiness
N/AChild safety
N/A